Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Oncogene - 22 Aug 2013

Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames D S, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar A F, Minna J D, Mori M

Abstract excerpt

KRAS mutations are one of the most common driver mutations in non-small-cell lung cancer (NSCLC) and finding druggable target molecules to inhibit oncogenic KRAS signaling is a significant challenge in NSCLC therapy. We recently identified epiregulin (EREG) as one of several putative transcriptional targets of oncogenic KRAS signaling in both KRAS-mutant NSCLC cells and immortalized bronchial epithelial cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Butadienes
Share to Epidermal Growth Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Mitogen-Activated Protein Kinases

Share to Nitriles

Share to Pyrazoles

Share to Pyridazines

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 22964644
DOI: 10.1038/onc.2012.402
PMCID: PMC4451140

Genes

KRAS
EREG
BRAF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.PMID 22964644Read ↗

The Role of EREG/EGFR Pathway in Tumor Progression.Semantic proximity Read ↗

Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells.Semantic proximity Read ↗

EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.Semantic proximity Read ↗

Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathwaySemantic proximity Read ↗

Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.Semantic proximity Read ↗

Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastomaSemantic proximity Read ↗

Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin.Semantic proximity Read ↗

Epiregulin increases stemness-associated genes expression and promotes chemoresistance of non-small cell lung cancer via ERK signalingSemantic proximity Read ↗

Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.Semantic proximity Read ↗

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.Semantic proximity Read ↗

Tumor fibroblast–derived epiregulin promotes growth of colitis-associated neoplasms through ERKSemantic proximity Read ↗

Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.